Tissue plasminogen activator and acute p
โ
Samuel Z. Goldhaber; Craig M. Kessler; John Heit; John E. Markis; G. V. R. K. Sh
๐
Article
๐
1988
๐
John Wiley and Sons
๐
English
โ 714 KB
We assessed the efficacy and safety of peripheral intravenous recombinant human tissue-type plasminogen activator (rt-PA) in 47 patients with angiographically documented pulmonary embolism (PE). We administered 50 mg/2 h and, if necessary, an additional 40 mg/4 h. By 6 hours, 94% of the patients had